Quick Answer
Marker Therapeutics, Inc. reported Operating Income Loss of -$12.89 million for the year ending 2025.
- Marker Therapeutics, Inc. showed a decrease of -15.9% in Operating Income Loss from 2024 to 2025.
- This data is from Marker Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2010 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: -$1.28 million | Q1 2011: -$1.10 million | Q2 2011: -$701.4 thousand | Q1 2012: -$671.8 thousand | Q2 2012: -$3.14 million | Q3 2012: -$796.7 thousand | Q2 2013: -$675.1 thousand | Q3 2013: -$313.3 thousand | Q1 2015: -$1.03 million | Q2 2015: -$1.14 million | Q3 2015: -$1.74 million | Q1 2016: -$1.75 million | Q2 2016: -$2.43 million | Q3 2016: -$2.72 million | Q1 2017: -$2.42 million | Q2 2017: -$2.39 million | Q3 2017: -$3.99 million | Q1 2018: -$3.20 million | Q2 2018: -$4.67 million | Q3 2018: -$4.43 million | Q1 2019: -$5.64 million | Q2 2019: -$5.87 million | Q3 2019: -$5.65 million | Q1 2020: -$6.64 million | Q2 2020: -$6.36 million | Q3 2020: -$7.38 million | Q1 2021: -$8.78 million | Q2 2021: -$10.91 million | Q3 2021: -$10.02 million | Q1 2022: -$9.79 million | Q2 2022: -$5.27 million | Q3 2022: -$5.83 million | Q1 2023: -$4.31 million | Q2 2023: -$4.13 million | Q3 2023: -$3.20 million | Q1 2024: -$2.55 million | Q2 2024: -$2.31 million | Q3 2024: -$2.40 million | Q1 2025: -$4.61 million | Q2 2025: -$4.26 million | Q3 2025: -$2.14 million.
- Over the full 15 years of available data (2010 to 2025), Marker Therapeutics, Inc.'s Operating Income Loss has declined by 135.6%.
- Historical annual values: Fiscal year 2025: -$12.89 million | Fiscal year 2024: -$11.12 million | Fiscal year 2023: -$14.58 million | Fiscal year 2022: -$19.79 million | Fiscal year 2021: -$39.48 million | Fiscal year 2020: -$28.89 million | Fiscal year 2019: -$22.53 million | Fiscal year 2018: -$148.17 million | Fiscal year 2017: -$11.48 million | Fiscal year 2016: -$8.49 million | Fiscal year 2015: -$6.16 million | Fiscal year 2014: -$3.37 million | Fiscal year 2013: -$2.66 million | Fiscal year 2011: -$3.32 million | Fiscal year 2010: -$5.47 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: